<DOC>
	<DOCNO>NCT02763761</DOCNO>
	<brief_summary>The purpose study compare effect Infliximab oral prednisone versus methylprednisolone oral prednisone patient melanoma , lung cancer , renal cell carcinoma immune relate Grade 3-4 diarrhea 3 day persistent Grade 2 diarrhea 5 day treatment Yervoy and/or Opdivo</brief_summary>
	<brief_title>An Investigational Study Infliximab With Prednisone Methylprednisolone Versus Prednisone Combination Treatment Immune Related Severe Diarrhea Patients Treated With Yervoy and/or Opdivo</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Subjects must melanoma lung cancer renal cell carcinoma receive ipilimumab nivolumab single treatment combination Subject must NCI common toxicity Grade 34 immunerelated diarrhea 3 day persistent Grade 2 diarrhea 5 day Subjects must discontinue ipilimumab nivolumab monotherapy combination regimen Subjects receive anti Cytotoxic Tlymphocytic antigen ( CTLA4 ) ( nonipilimumab ) antiProgrammed death1 ( PD1 ) ( nonnivolumab ) treatment Subjects treat systemic Corticosteroid ( CST ) within 1 week randomization subject treat infliximab within 7 week randomization Subjects know history tuberculosis Subjects immunosuppressive disease require use systemic steroid immunosuppressive treatment Subjects allergic infliximab , inactive component infliximab , murine protein methylprednisolone Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>